کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5952575 | 1173295 | 2016 | 19 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The A's Have It
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
AHRApoA-IABCA1OVAHDLIgELPShigh-density lipoprotein - HDL یا لیپوپروتئین با دانسیته بالا یا چگالی بالاAsthma - آسمApolipoprotein A-I - آپولیپوپروتئین A-IAirway inflammation - التهاب راه های هواییOvalbumin - اوبلبومین IgE, immunoglobulin E - ایمونوگلوبولین EBALF - بافتBAL fluid - شیر مایعGranulocyte-colony stimulating factor - فاکتور تحریک گرانولیسیت کلنیG-CSF - فاکتور محرک کُلونی گرانولوسیتlipopolysaccharide - لیپوپلی ساکاریدAirway hyperresponsiveness - پاسخگویی فوریLipids - چربیها
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
New treatments are needed for patients with asthma who are refractory to standard therapies, such as individuals with a phenotype of “type 2-low” inflammation. This important clinical problem could potentially be addressed by the development of apolipoprotein A-I (apoA-I) mimetic peptides. ApoA-I interacts with its cellular receptor, the ATP-binding cassette subfamily A, member 1 (ABCA1), to facilitate cholesterol efflux out of cells to form nascent high-density lipoprotein particles. The ability of the apoA-I/ABCA1 pathway to promote cholesterol efflux from cells that mediate adaptive immunity, such as antigen-presenting cells, can attenuate their function. Data from experimental murine models have shown that the apoA-I/ABCA1 pathway can reduce neutrophilic airway inflammation, primarily by suppressing the production of granulocyte-colony stimulating factor. Furthermore, administration of apoA-I mimetic peptides to experimental murine models of allergic asthma has decreased both neutrophilic and eosinophilic airway inflammation, as well as airway hyperresponsiveness and mucous cell metaplasia. Higher serum levels of apoA-I have also been associated with less severe airflow obstruction in patients with asthma. Collectively, these results suggest that the apoA-I/ABCA1 pathway may have a protective effect in asthma, and support the concept of advancing inhaled apoA-I mimetic peptides to clinical trials that can assess their safety and effectiveness. Thus, we propose that the development of inhaled apoA-I mimetic peptides as a new treatment could represent a clinical advance for patients with severe asthma who are unresponsive to other therapies.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Chest - Volume 150, Issue 2, August 2016, Pages 283-288
Journal: Chest - Volume 150, Issue 2, August 2016, Pages 283-288
نویسندگان
Xianglan MD, PhD, Elizabeth M. PhD, Amisha V. MBBS, MHS, Alan T. MD, PhD, Stewart J. MD,